3C study

https://www.neurodegenerationresearch.eu/survey/3c-study/

Title of cohort

3C study

Acronym for cohort

3C

Name of Principal Investigator - Title

Prof

Name of Principal Investigator - First name

Christophe

Name of Principal Investigator - Last name

Tzourio

Address of institution -Institution

INSERM - U1219

Address of institution - Street address

146 rue Léo-Saignat

Address of institution - City

Bordeaux Cedex

Address of institution - Postcode

33076

Country

France

Website

http://www.three-city-study.com/

Contact email

Funding source

Inserm, CNRS, universités, MGEN, CNAM-TS, ISPED, DGS, GIS Institut de longévité, FDF, Conseils régionaux d'Aquitaine et de Bourgogne, Ministère chargé de la recherche, Agence

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

Alzheimer's disease and other dementias

Q1b. When are studies on the above condition(s) expected to become possible?

Already possible

Q2a. In a single sentence what is the stated aim of the cohort?

Study the impact of vascular factors on dementia risk in the over 65 population.

Q2b. What distinguishes this cohort from other population cohorts?
Q3a. i) Number of publications that involve use of your cohort to date

372

Q3a.ii) Please give up to three examples of studies to date (Principal Investigator, Institution, Title of Study)
Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available

http://www.three-city-study.com/publications.php

Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the population
Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:

65

Q4a. Study criteria: what is the age range of participants at recruitment? To:

until death

Q4b. Study criteria: what are the inclusion criteria?

65 or more years old subjects, inscribed on the electoral lists, and having a phone

Q4c. Study criteria: what are the exclusion criteria?

None

Q5. What is the size of the cohort (i.e. how many participants have enrolled)?

5,001-10,000 participants

Q6a. Please describe what measures are used to characterise participants

medical examination, psychometric tests

Q6b. Are there additional measures for participants with a clinical disorder?

Additional psychometric tests

Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?

No

If yes please specify
Q7. What is the study design (select all that apply)?

Prospective cohort|Longitudinal

Q8. Are your cases matched by
Q9a. Does your study include a specialised subset of control participants?

No

Q9b. If your study includes a specialised subset of control participants please describe
Q10a. i) Please enter the data collection start date

01/01/1999

Q10a. ii) Please enter the data collection end date

01/01/2016

Q10a. iii) Is data collection for this study

Data analysis ongoing

Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

Yes - funding applied for/funding awarde

Q11. Is data collected

Through links to medical records

Other please specify here

CNAMTS, PMSI

Q12. Is there a system in place to enable re-contact with patients to ask about participation in future studies?

No

Q13a. Please give information on the format and availability of data stored in a database (1)

Data summarised in database

% available

100

Q13a. Please give information on the format and availability of data stored in a database (2)

Database is web-based

% available

100

Q13a. Please give information on the format and availability of data stored in a database (3)

No

% available
Q13a. Please give information on the format and availability of data stored in a database (4)

No

% available
Other (please specify)
% available
Q13b. Please give information on the format and availability of data held as individual records (1)

Data is held as individual records

% available

100

Q13b. Please give information on the format and availability of data held as individual records (2)

No

% available
Q13b. Please give information on the format and availability of data held as individual records (3)

No

% available
Q13b. Please give information on the format and availability of data held as individual records (4)

No

% available
Please specify language used
Q14a. Is data available to other groups?

Yes

Q14b. If data is available to other groups what is the access policy/mechanisms for access?

Apply to PI or co-ordinator at resource| Access committee mechanism| Access committee mechanism| National access| International access| Access to industry

Q15. What data sharing policy is specified as a condition of use?

Data made publicly available after a specified time point

Q16a. Are tissues/samples/DNA available to other groups?

Yes

Q16b i) If yes, please describe below:

Living donors blood| Living donors: blood derivatives| Living donors: DNA

Q16b. ii) In what form are tissues/samples/DNA supplied?

Primary Samples: Stabilised samples (frozen or fixed)

Q16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

Yes

Q17. Is information on biological characteristics available to other groups?

Yes, for all the cohort

Number of Patients
% of total cohort

Types:
Population Cohorts

Member States:
France

Diseases:
Alzheimer's disease & other dementias

Years:
2016

Database Categories:
N/A

Database Tags:
N/A